Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Maj 2025

Genmab — Maj 2025

Planlagt Fastgjort Låst Flyttet Genmab
308 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #201

    @RobertoBoreaMD

    Final #CHRYSALIS trials results: #Amivantamab delivers durable responses in #METex14 #NSCLC, even after MET TKI failure. https://x.com/RobertoBoreaMD/status/1924563968221122751

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #202

      The efficacy and safety of Tisotumab vedotin in the treatment of recurrent/metastatic cervical cancer: a systematic review and meta-analysis of single-arm studies https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1538980/full

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #203

        wow....
        ODAC Votes STARGLO Trial Not Applicable to US Patients With DLBCL https://www.targetedonc.com/view/odac-votes-starglo-trial-not-applicable-to-us-patients-with-dlbcl

        1 Reply Last reply
        0
        • L Offline
          L Offline
          lahn1
          wrote on sidst redigeret af
          #204

          ja tak ! men det er desværre nok kun en stakket rist. Alt ser jo fint ud undtagen at de alt for få USA patienter, som koster dem godkendelsen. Kan de mon få lov til at rekruttere nogle flere USA patienter og og på den måde udvide US-n ?

          1 Reply Last reply
          0
          • L Offline
            L Offline
            lahn1
            wrote on sidst redigeret af
            #205

            rist = frist

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #206

              ODAC is an Advisory Committee; so the FDA could even theoretically deviate from their advice. But they can also follow it and there is not enough confirmation for full approval and approval could be withdrawn. Genentech could recruit additional US patients; but it would take years wouldn't it...

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #207

                maybe there is more in here, i didn't go through it -
                Oncologic Drugs Advisory Committee (ODAC) Meeting
                May 20, 2025- https://www.fda.gov/media/186525/download

                1 Reply Last reply
                0
                • L Offline
                  L Offline
                  lahn1
                  wrote on sidst redigeret af
                  #208

                  ODAC 6-2 i favør for Darzalex i SMM

                  1 Reply Last reply
                  0
                  • Helge_LarsenPI-redaktørH Offline
                    Helge_LarsenPI-redaktørH Offline
                    Helge_LarsenPI-redaktør
                    wrote on sidst redigeret af
                    #209

                    Godmorgen 🙂

                    1 Reply Last reply
                    0
                    • P Offline
                      P Offline
                      ProinvestorNEWS
                      wrote on sidst redigeret af
                      #210

                      FDA cancer panel gives thumbs up to J&J's Darzalex, votes nay on Roche's Columvi https://firstwordpharma.com/story/5964785

                      1 Reply Last reply
                      0
                      • L Offline
                        L Offline
                        LP90
                        wrote on sidst redigeret af
                        #211

                        Godmorgen 🙂

                        1 Reply Last reply
                        0
                        • T Offline
                          T Offline
                          transalp
                          wrote on sidst redigeret af
                          #212

                          Go morgen.. 🙂

                          1 Reply Last reply
                          0
                          • B Offline
                            B Offline
                            bibob
                            wrote on sidst redigeret af
                            #213

                            God morgen. 🙂

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #214

                              Dr Falchi on the Safety of Fixed-Duration Epcoritamab Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma https://www.onclive.com/view/dr-falchi-on-the-safety-of-fixed-duration-epcoritamab-plus-lenalidomide-rituximab-in-r-r-follicular-lymphoma

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #215

                                JNJ press release - U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma - https://www.jnj.com/media-center/press-releases/u-s-fda-oncologic-drugs-advisory-committee-votes-in-favor-of-the-benefit-risk-profile-of-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-for-high-risk-smoldering-multiple-myeloma

                                1 Reply Last reply
                                0
                                • N Offline
                                  N Offline
                                  NiklasZ
                                  wrote on sidst redigeret af
                                  #216

                                  Så er aktien brudt ud af den nedadgående trend kanal igen. Lad os se om det kan holde denne gang.

                                  1 Reply Last reply
                                  0
                                  • SolsenS Offline
                                    SolsenS Offline
                                    Solsen
                                    wrote on sidst redigeret af
                                    #217

                                    Ret interessant melding på Columvi. Stoffet virker tilsyneladende ikke så godt på non-asiatiske pts.

                                    1 Reply Last reply
                                    0
                                    • P Offline
                                      P Offline
                                      Plimsoller
                                      wrote on sidst redigeret af
                                      #218

                                      Enig Solsen, og som E L skrev, så vil et nyt fase 3 studie med flere US pts tage år.

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #219

                                        I guess the moral of the story is if you lost money in the first quarter in biotech, you have plenty of good company. https://x.com/MBbiotech/status/1925123717287346356

                                        1 Reply Last reply
                                        0
                                        • G Offline
                                          G Offline
                                          gentogen
                                          wrote on sidst redigeret af
                                          #220

                                          Egentlig ret utroligt, at de ikke havde styr på deres geografiske fordeling af patienter, men ifølge oprindelige link fra EL, så havde kun få af de i princippet medvirkende amerikanske klinikker i praksis deltaget

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper